Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
3.680
+0.220 (6.36%)
At close: Apr 6, 2026, 4:00 PM EDT
3.750
+0.070 (1.90%)
After-hours: Apr 6, 2026, 7:12 PM EDT
Prelude Therapeutics Employees
Prelude Therapeutics had 79 employees as of December 31, 2025. The number of employees decreased by 52 or -39.69% compared to the previous year.
Employees
79
Change (1Y)
-52
Growth (1Y)
-39.69%
Revenue / Employee
$153,671
Profits / Employee
-$1,259,468
Market Cap
303.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 79 | -52 | -39.69% |
| Dec 31, 2024 | 131 | 3 | 2.34% |
| Dec 31, 2023 | 128 | 6 | 4.92% |
| Dec 31, 2022 | 122 | 6 | 5.17% |
| Sep 30, 2022 | 120 | 7 | 6.19% |
| Jun 30, 2022 | 112 | 12 | 12.00% |
| Mar 31, 2022 | 118 | 13 | 12.38% |
| Dec 31, 2021 | 116 | 48 | 70.59% |
| Sep 30, 2021 | 113 | 58 | 105.45% |
| Jun 30, 2021 | 100 | 49 | 96.08% |
| Mar 31, 2021 | 105 | 54 | 105.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Abeona Therapeutics | 226 |
| Adlai Nortye | 123 |
| AC Immune | 122 |
| Foghorn Therapeutics | 106 |
| C4 Therapeutics | 104 |
| Silence Therapeutics | 88 |
| SAB Biotherapeutics | 86 |
| Protara Therapeutics | 46 |
PRLD News
- 20 days ago - Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting - GlobeNewsWire
- 27 days ago - Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 - GlobeNewsWire
- 2 months ago - Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor - GlobeNewsWire
- 4 months ago - Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs - GlobeNewsWire
- 4 months ago - PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 5 months ago - Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm - Business Wire
- 5 months ago - Prelude Therapeutics Announces Strategic Business Update - GlobeNewsWire